Breast lesions examined by digital angiography. Work in progress

The Role of Contrast-Enhanced Mammography After Cryoablation of Breast Cancer

Image-guided cryoablation is an emerging therapeutic technique for the treatment of breast cancer and is a treatment strategy that is an effective alternate to surgery in select patients. Tumor features impacting the efficacy of cryoablation include size, location in relation to skin, and histology (e.g., extent of intraductal component), underscoring the importance of imaging for staging and workup in this patient population. Contrast-enhanced mammography (CEM) utilization is increasing in both the screening and diagnostic settings and may be useful for follow-up imaging after breast cancer cryoablation, given its high sensitivity for cancer detection and its advantages in terms of PPV, time, cost, eligibility, and accessibility compared with contrast-enhanced MRI. This Clinical Perspective describes the novel use of CEM after breast cancer cryoablation, highlighting the advantages and disadvantages of CEM compared with alternate imaging modalities, expected benign postablation CEM findings, and CEM findings suggestive of residual or recurrent tumor.

Contrast-enhanced mammography: past, present, and future

Contrast-enhanced mammography (CEM) combines conventional mammography with iodinated contrast material to improve cancer detection. CEM has comparable performance to breast MRI without the added cost or time of conventional MRI protocols. Thus, this technique may be useful for indications previously reserved for MRI, such as problem-solving, determining disease extent in patients with newly diagnosed cancer, monitoring response to neoadjuvant therapy, evaluating the posttreatment breast for residual or recurrent disease, and potentially screening in women at intermediate- or high-risk for breast cancer. This article will provide a comprehensive overview on the past, present, and future of CEM, including its evolving role in the diagnostic and screening settings.

Pearls and Pitfalls of Contrast-Enhanced Mammography

Contrast-enhanced mammography (CEM) is a promising new imaging modality that uses a dual-energy acquisition to provide both morphologic and vascular assessment of breast lesions. Although no official BI-RADS lexicon exists, interpretation entails using the mammographic BI-RADS lexicon in combination with that for breast MRI. CEM has comparable performance to breast MRI, with sensitivity of 93-100% and specificity of 80-94%. Currently FDA approved for diagnostic imaging, this technology can be helpful in determining disease extent in patients with newly diagnosed breast malignancy, monitoring response to neoadjuvant therapy, identifying mammographically occult malignancies, and diagnostic problem-solving. Studies are ongoing about its role in screening, especially in women with dense breasts or at elevated risk. There are some challenges to successful implementation into practice, but overall, patients tolerate the study well, and exam times are less than the full breast MRI protocol.

Quantitative analysis of enhanced malignant and benign lesions on contrast-enhanced spectral mammography

OBJECTIVE

To retrospectively analyze the quantitative measurement and kinetic enhancement among pathologically proven benign and malignant lesions using contrast-enhanced spectral mammography (CESM).

METHODS

We investigated the differences in enhancement between 44 benign and 108 malignant breast lesions in CESM, quantifying the extent of enhancements and the relative enhancements between early (between 2-3 min after contrast medium injection) and late (3-6 min) phases.

RESULTS

The enhancement was statistically stronger in malignancies compared to benign lesions, with good performance by the receiver operating characteristic curve [0.877, 95% confidence interval (0.813-0.941)]. Using optimal cut-off value at 220.94 according to Youden index, the sensitivity was 75.9%, specificity 88.6%, positive likelihood ratio 6.681, negative likelihood ratio 0.272 and accuracy 82.3%. The relative enhancement patterns of benign and malignant lesions, showing 29.92 vs 73.08% in the elevated pattern, 7.14 vs 92.86% in the steady pattern, 5.71 vs 94.29% in the depressed pattern, and 80.00 vs 20.00% in non-enhanced lesions (p < 0.0001), respectively.

CONCLUSION

Despite variations in the degree of tumour angiogenesis, quantitative analysis of the breast lesions on CESM documented the malignancies had distinctive stronger enhancement and depressed relative enhancement patterns than benign lesions. Advances in knowledge: To our knowledge, this is the first study evaluating the feasibility of quantifying lesion enhancement on CESM. The quantities of enhancement were informative for assessing breast lesions in which the malignancies had stronger enhancement and more relative depressed enhancement than the benign lesions.

Contrast-enhanced digital mammography

Mammography is the only technology documented to reduce breast cancer mortality. Its sensitivity, however, is 75% to 80% at best and reduced to 30% to 50% in women with dense breasts. MR imaging is a sensitive modality for the detection of breast cancer but cannot be used in all patients. Its sensitivity is due in large part to its ability to detect enhancement of tumor vascularity so cancers can be detected before a mass is present. Contrast-enhanced dual-energy mammography uses the same capability of vascular enhancement and has been demonstrated to be more sensitive than routine mammography.

Digital mammography: novel applications

This article discusses the limitations of current imaging modalities in detecting and characterizing tumors in breast tissue. It then explores some potential advanced applications in digital mammography, such as contrast-enhanced mammography, breast tomosynthesis, and dual modality mammographic fusion, that are being investigated to capitalize on the strengths of the digital platform and to realize fully the potential benefits of enhanced detection anticipated from digital mammography.

Initial clinical experience with contrast-enhanced digital breast tomosynthesis

RATIONALE AND OBJECTIVES

Contrast-enhanced digital mammography and digital breast tomosynthesis are two imaging techniques that attempt to increase malignant breast lesion conspicuity. The combination of these into a single technique, contrast-enhanced digital breast tomosynthesis (CE-DBT), could potentially integrate the strengths of both. The objectives of this study were to assess the clinical feasibility of CE-DBT as an adjunct to digital mammography, and to correlate lesion enhancement characteristics and morphology obtained with CE-DBT to digital mammography, ultrasound, and magnetic resonance (MR).

MATERIALS AND METHODS

CE-DBT (GE Senographe 2000D; Milwaukee, WI) was performed as a pilot study in an ongoing National Cancer Institute-funded grant (P01-CA85484) studying multimodality breast imaging. Thirteen patients with ACR BI-RADS category 4 or 5 breast lesions underwent imaging with digital mammography, ultrasound, MR, and CE-DBT. CE-DBT was performed at 49 kVp with a rhodium target and a 0.27-mm copper (Alfa Aesar, Ward Hill, MA) filter. Preinjection and postinjection DBT image sets were acquired in the medial lateral oblique projection with slight compression. Each image set consists of nine images acquired over a 50-degree arc and was obtained with a mean glandular x-ray dose comparable to two conventional mammographic views. Between the precontrast and postcontrast DBT image sets, a single bolus of iodinated contrast agent (1 ml/kg at 2 ml/s, Omnipaque-300; Amersham Health Inc., Princeton, NJ) was administered. Images were reconstructed using filtered-backprojection in 1-mm increments and transmitted to a clinical PACS workstation.

RESULTS

Initial experience suggests that CE-DBT provides morphologic and vascular characteristics of breast lesions qualitatively concordant with that of digital mammography and MR.

CONCLUSION

As an adjunct to digital mammography, CE-DBT may be a potential alternative tool for breast lesion morphologic and vascular characterization.

Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography

OBJECTIVE

The purpose of this article is to assess the accuracy of contrast-enhanced digital mammography in the detection of breast carcinoma and to correlate the findings on the images with those of histologic analysis using microvessel quantification.

SUBJECTS AND METHODS

Twenty patients with a suspicious breast abnormality underwent contrast-enhanced digital mammography using a full-field digital mammography unit that was modified to detect iodinated enhancement. For each patient, a total of six contrast-enhanced craniocaudal views were acquired from 30 seconds to 7 minutes after the injection of a bolus of 100 mL of an iodinated contrast agent. Image processing included a logarithmic subtraction and the analysis of enhancement kinetic curves. Contrast-enhanced digital mammography findings were compared with histologic analysis of surgical specimens, including intratumoral microvessel density quantification evaluated on CD34-immunostained histologic sections obtained from all patients.

RESULTS

An area of enhancement was depicted on contrast-enhanced digital mammograms in 16 of the 20 histologically proven breast carcinomas. Excellent correlation was seen between the size of enhancement and the histologic size of tumors, which ranged from 9 to 22 mm. Early enhancement with washout was observed in four cases, early enhancement followed by a plateau in four cases, gradual enhancement in seven cases, and unexpected decrease of enhancement in one case. Intratumoral microvessel density ranged from 11.7 to 216.6 microvessels per square millimeter. A poor correlation was found between data measured on contrast-enhanced digital mammography and intratumoral microvessel density measured on CD34-immunostained histologic sections.

CONCLUSION

Contrast-enhanced digital mammography is able to depict angiogenesis in breast carcinoma. Breast compression and projective images acquisition alter the quantitative assessment of enhancement parameters.

Evaluation of the minimum iodine concentration for contrast-enhanced subtraction mammography

Early manifestation of breast cancer is often very subtle and is displayed in a complex and variable pattern of normal anatomy that may obscure the disease. The use of dual-energy techniques, that can remove the structural noise, and contrast media, that enhance the region surrounding the tumour, could help us to improve the detectability of the lesions. The aim of this work is to investigate the use of an iodine-based contrast medium in mammography with two different double exposure techniques: K-edge subtraction mammography and temporal subtraction mammography. Both techniques have been investigated by using an ideal source, like monochromatic beams produced at a synchrotron radiation facility and a clinical digital mammography system. A dedicated three-component phantom containing cavities filled with different iodine concentrations has been developed and used for measurements. For each technique, information about the minimum iodine concentration, which provides a significant enhancement of the detectability of the pathology by minimizing the risk due to high dose and high concentration of contrast medium, has been obtained. In particular, for cavities of 5 and 8 mm in diameter filled with iodine solutions, the minimum concentration needed to obtain a contrast-to-noise ratio of 5 with a mean glandular dose of 2 mGy has been calculated. The minimum concentrations estimated with monochromatic beams and K-edge subtraction mammography are 0.9 mg ml(-1) and 1.34 mg ml(-1) for the biggest and smallest details, respectively, while for temporal subtraction mammography they are 0.84 mg ml(-1) and 1.31 mg ml(-1). With the conventional clinical system the minimum concentrations for the K-edge subtraction mammography are 4.13 mg ml(-1) (8 mm diameter) and 5.75 mg ml(-1) (5 mm diameter), while for the temporal subtraction mammography they are 1.01 mg ml(-1) (8 mm diameter) and 1.57 mg ml(-1) (5 mm diameter).

Positron emission mammography: high-resolution biochemical breast imaging

Positron emission mammography (PEM) provides images of biochemical activity in the breast with spatial resolution matching individual ducts (1.5 mm full-width at half-maximum). This spatial resolution, supported by count efficiency that results in high signal-to-noise ratio, allows confident visualization of intraductal as well as invasive breast cancers. Clinical trials with a full-breast PEM device have shown high clinical accuracy in characterizing lesions identified as suspicious on the basis of conventional imaging or physical examination (sensitivity 93%, specificity 83%, area under the ROC curve of 0.93), with high sensitivity preserved (91%) for intraductal cancers. Increased sensitivity did not come at a cost of reduced specificity. Considering that intraductal cancer represents more than 30% of reported cancers, and is the form of cancer with the highest probability of achieving surgical cure, it is likely that the use of PEM will complement anatomic imaging modalities in the areas of surgical planning, high-risk monitoring, and minimally invasive therapy. The quantitative nature of PET promises to assist researchers interested studying the response of putative cancer precursors (e.g., atypical ductal hyperplasia) to candidate prevention agents.

Dual-energy contrast-enhanced digital subtraction mammography: feasibility

A technique for demonstrating breast cancers, dual-energy contrast agent-enhanced digital subtraction mammography, was performed in 26 subjects with mammographic or clinical findings that warranted biopsy. The technique consists of high-energy and low-energy digital mammography after administration of iodinated contrast agent. Weighted subtraction of the logarithmic transform of these images is then performed to obtain an image that preferentially shows iodine. Of the 26 subjects, 13 had invasive cancers. Eleven of these tumors enhanced strongly, one enhanced moderately, and one enhanced weakly. The duct in one patient with ductal carcinoma in situ was weakly enhancing. In the other 12 patients, benign tissue enhanced diffusely in two and weakly focally in two. These results indicate that the technique is feasible and worthy of further study.

Contrast-enhanced digital mammography: initial clinical experience

PURPOSE

To investigate the potential of using intravenous contrast material with full-field digital mammography to facilitate the detection and characterization of lesions in the breast.

MATERIALS AND METHODS

Twenty-two women scheduled for biopsy because they were suspected of having abnormalities at breast imaging underwent imaging with contrast material-enhanced digital mammography. Six sequential images of the affected breast were obtained, with a contrast agent injected intravenously between the time the first and second images were obtained. Image processing included registration and logarithmic subtraction. Lesions were evaluated for the presence, morphology, and kinetics of enhancement. Lesion type, size, and pathologic findings were correlated with the findings at contrast-enhanced digital mammography.

RESULTS

At contrast-enhanced digital mammography, enhancement was observed in eight of 10 patients with biopsy-proved cancers. In one case of ductal carcinoma in situ and one case of invasive ductal carcinoma, enhancement was not observed. No enhancement was seen in seven of 12 cases in which lesions were suspected of being malignant at initial imaging but were benign. Morphology generally correlated with the pathologic diagnosis. The kinetics of lesion enhancement showed similarity to that seen with gadolinium-enhanced magnetic resonance imaging but was not consistent.

CONCLUSION

The results of this preliminary study suggest that contrast-enhanced digital mammography potentially may be useful in identification of lesions in the mammographically dense breast. Further investigation of contrast-enhanced digital mammography as a diagnostic tool for breast cancer is warranted.

Development of contrast digital mammography

Development of breast tumors is often accompanied by angiogenesis--the formation of new blood vessels. It is possible to image the effects of this process by tracking the uptake and washout of contrast agents in the vicinity of a lesion. In this article, a method for carrying out contrast subtraction mammography on a full-field digital mammography unit is described. Spectral measurements and modeling were performed to optimize the choice of x-ray target, kilovoltage and x-ray beam filtration for contrast digital mammography (CDM) on an available digital mammography system. Phantom studies were carried out to determine the sensitivity of CDM to iodine. Detection of iodine area densities of 0.3 mg/cm2 is possible for a circular object with a radius of 1.3 mm, which allows detection of uptake levels in the breast typically seen with cancer and some benign breast conditions. It was found that with a molybdenum anode x-ray tube, copper filtration could be used to effectively shape the x-ray spectrum to maximize the proportion of x rays with energies above the k edge of iodine. Simple logarithmic subtraction was found to be adequate in suppressing background signals dependent on the x-ray beam intensity and background thickness of the breast. The total x-ray dose from the procedure ranges between 1 and 3 mGy, similar to that from a conventional single view film mammogram. A clinical pilot study is currently being carried out to evaluate this technique.

Analysis of the tumor staining obtained by preoperative IV-DSA for breast cancer patients: density and metastasis correlation

We examined the density of tumor enhancement on intravenous digital subtraction angiography (IV-DSA) in patients with breast cancer in relation to disease-free survival. The subjects of the present study consisted of 103 patients with invasive ductal carcinoma measuring 5 cm or less treated from July 1988 to September 1993. In the 103 patients, 15 had distant metastasis. The region of interest was set in the areas enhanced by IV-DSA of the breast. The maximum density (MAX) was calculated by the time-density curve. When the patients were divided according to three classes of MAX, i.e., 0-5.0 pixels (group A, n = 23), 5.1-9.0 pixels (group B, n = 50), 9.1 pixels or more (group C, n = 30), disease-free survival was highest in group A followed by group B and C, respectively. The disease-free survival rate in group C was significantly lower than that of group A or B (p < 0.05). Thus, high values of MAX were associated with low rates of disease-free survival. Since the value of MAX was found to be independent from other prognostic factors by multivariate analysis, these results indicate that MAX has a close correlation with metastasis or recurrence of breast cancer, making IV-DSA a promising prognostic factor.

Recent developments in breast imaging

A review of breast imaging has already appeared in 1982 in this journal. Consequently, the present article concentrates on a discussion of only those developments of a more recent nature. Although the emphasis is placed on the physical aspects of the different imaging methods concerned, the essential factors relating to the clinical background and the associated radiation risk are also outlined. The completeness of detail depends on the present clinical importance of the method under discussion. X-ray mammography, which is still the most important breast imaging technique and has proved to be an effective method for breast cancer screening, is therefore treated in greater detail. Since the early 1980s, ultrasound B-mode scanning has evolved to an indispensable adjunct to x-ray mammography. For Doppler sonography, diaphanography, contrast-enhanced MRI, CT and DSA, the visualization of a tumour depends essentially on the enhanced vascularity of the lesion. Whether this will prove to be a reliable indicator for malignancy remains to be shown in controlled clinical studies. Common to all imaging systems is the increasing use of digital methods for signal processing, which also offers the possibility of computer-aided diagnosis by texture analysis and pattern recognition.